Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability

American Journal of Physiology - Cell Physiology

Volumn 300, Issue 1, 2011, Pages

  Byfield, Fitzroy J ^a   Wen, Qi ^a   Leszczyńska, Katarzyna ^b   Kułakowska, Alina ^a,b   Namiot, Zbigniew ^b   Janmey, Paul A ^a   Bucki, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cytoskeleton; Endothelium

Indexed keywords

ACTIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; F ACTIN; PURINERGIC P2X7 RECEPTOR; SPHINGOSINE 1 PHOSPHATE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; CELL JUNCTION; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL STIFFNESS; CYTOSKELETON; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RIGIDITY; UMBILICAL VEIN ENDOTHELIAL CELL;

ACTINS; ADHERENS JUNCTIONS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; AORTA; CATTLE; CELL MEMBRANE; CELLS, CULTURED; CYTOSKELETON; ENDOTHELIAL CELLS; HUMANS; MICE; PERMEABILITY;

BOVINAE;

EID: 78651363517     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00158.2010     Document Type: Article

References (38)

1. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95: 9541-9546, 1998.
2. Berkestedt I, Nelson A, Bodelsson M. Endogenous antimicrobial peptide LL-37 induces human vasodilatation. Br J Anaesth 100: 803-809, 2008.
3. Birukova AA, Arce FT, Moldobaeva N, Dudek SM, Garcia JG, Lal R, Birukov KG. Endothelial permeability is controlled by spatially defined cytoskeletal mechanics: atomic force microscopy force mapping of pulmonary endothelial monolayer. Nanomedicine 5: 30-41, 2009.
4. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77: 451-459, 2005.
5. Bowdish DM, Davidson DJ, Scott MG, Hancock RE. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49: 1727-1732, 2005.
6. Bucki R, Leszczynska K, Namiot A, Sokolowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp (Warsz) 58: 15-25, 2010.
7. Bucki R, Pastore JJ, Randhawa P, Vegners R, Weiner DJ, Janmey PA. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob Agents Chemother 48: 1526-1533, 2004.
8. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother 60: 535-545, 2007.
9. Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R. Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros 3: 45-50, 2004.
10. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192: 1069-1074, 2000.
11. Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC, Mietzner TA. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother 49: 3208-3216, 2005.
12. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172: 4987-4994, 2004.
13. Ferrari D, Pizzirani C, Gulinelli S, Callegari G, Chiozzi P, Idzko M, Panther E, Di Virgilio F. Modulation of P2X7 receptor functions by polymyxin B: crucial role of the hydrophobic tail of the antibiotic molecule. Br J Pharmacol 150: 445-454, 2007.
14. Huang H, Sylvan J, Jonas M, Barresi R, So PT, Campbell KP, Lee RT. Cell stiffness and receptors: evidence for cytoskeletal subnetworks. Am J Physiol Cell Physiol 288: C72-C80, 2005.
15. Huang LC, Petkova TD, Reins RY, Proske RJ, McDermott AM. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci 47: 2369-2380, 2006.
16. Hubner S, Couvillon AD, Kas JA, Bankaitis VA, Vegners R, Carpenter CL, Janmey PA. Enhancement of phosphoinositide 3-kinase (PI 3-kinase) activity by membrane curvature and inositol-phospholipid-binding peptides. Eur J Biochem 258: 846-853, 1998.
17. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 19: 491-511, 2006.
18. Kerr SW, Yu R, Stearns CD, Haynes NA, Winquist RJ. Characterization of the polymorphonuclear leukocyte-induced vasoconstriction in isolated human umbilical veins. J Pharmacol Exp Ther 287: 640-647, 1998.
19. Leszczynska K, Namiot A, Fein DE, Wen Q, Namiot Z, Savage PB, Diamond S, Janmey PA, Bucki R. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 9: 187, 2009.
20. Levental I, Georges PC, Janmey PA. Soft biological matherials and their impact on cell function. Soft Matter 1: 299-306, 2007.
21. Liu X, Wu W, Li Q, Huang X, Chen B, Du J, Zhao K, Huang Q. Effect of sphingosine 1-phosphate on morphological and functional responses in endothelia and venules after scalding injury. Burns 35: 1171-1179, 2009.
22. 2+ mediates rac activation and adherens junction assembly in endothelial cells. J Biol Chem 280: 17320-17328, 2005.
23. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367, 2006.
24. Moy AB, Blackwell K, Wang N, Haxhinasto K, Kasiske MK, Bodmer J, Reyes G, English A. Phorbol ester-mediated pulmonary artery endothelial barrier dysfunction through regulation of actin cytoskeletal mechanics. Am J Physiol Lung Cell Mol Physiol 287: L153-L167, 2004.
25. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 172: 3070-3077, 2004.
26. Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 176: 3044-3052, 2006.
27. Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochem Soc Trans 36: 149-155, 2008.
28. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 31: 1066-1075, 2001.
29. Otte JM, Zdebik AE, Brand S, Chromik AM, Strauss S, Schmitz F, Steinstraesser L, Schmidt WE. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept 156: 104-117, 2009.
30. Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 19: 1646-1656, 2005.
31. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97: 3951-3959, 2001.
32. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N, Rabe KF, Hiemstra PS. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 171: 6690-6696, 2003.
33. Tomasinsig L, Pizzirani C, Skerlavaj B, Pellegatti P, Gulinelli S, Tossi A, Virgilio FD, Zanetti M. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Biol Chem 283: 30471-30481, 2008.
34. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, McCray PB Jr, Lehrer RI, Welsh MJ, Tack BF. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 68: 2748-2755, 2000.
35. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann NY Acad Sci 1123: 134-145, 2008.
36. Wang Y, Agerberth B, Lothgren A, Almstedt A, Johansson J. Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J Biol Chem 273: 33115-33118, 1998.
37. Wang Y, Johansson J, Agerberth B, Jornvall H, Griffiths WJ. The antimicrobial peptide LL-37 binds to the human plasma protein apolipoprotein A-I. Rapid Commun Mass Spectrom 18: 588-589, 2004.
38. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL-37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 28: 738-745, 2003.